Polymorphisms of Vascular Endothelial Growth Factor and Retinopathy of Prematurity

Ali, Aliaa A.; Hussien, Nouran F; Samy, Rania Mohamed; Husseiny, Khalid Al

doi:10.3928/01913913-20150506-02

Cited by 14 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors suggested that the correlation of genetic variants in VEGF genotypes with the outcomes of ROP and ROP requiring treatment may be due to linkage disequilibrium with nearby angiogenic genes with unknown genetic variants. Additionally, carriage of the −634C>G allele has been shown to independently increase the risk of BPD and ROP in Japanese and Egyptian neonates, respectively, while the 936CT allele did not ( 30 , 31 ). Although these studies focused on BPD and ROP individually, comparison of these studies highlights the importance of reviews to synthesize research across multiple disease processes.…”

Section: Vegf Polymorphismsmentioning

confidence: 97%

A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases

et al. 2018

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) are common and significant morbidities of prematurely born infants. These diseases have in common altered and pathologic vascular formation in the face of incomplete organ development. Therefore, it is reasonable to question whether factors affecting angiogenesis could have a joint pathogenic role for both diseases. Inhibition or induced expression of a single angiogenic factor is unlikely to be 100% causative or protective of either of BPD or ROP. It is more likely that interactions of multiple factors leading to disordered angiogenesis are present, increasing the likelihood of common pathways in both diseases. This review explores this possibility by assessing the evidence showing involvement of specific angiogenic factors in the vascular development and maldevelopment in each disease. Theoretical interactions of specific factors mutually contributing to BPD and ROP are proposed and, where possible, a timeline of the proposed relationships between BPD and ROP is developed. It is hoped that future research will be inspired by the theories put forth in this review to enhance the understanding of the pathogenesis in both diseases.

show abstract

Section: Vegf Polymorphismsmentioning

confidence: 97%

A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Genetic association studies with ROP and VEGF gene have been contradictory. 15,33,87,99,142,176,197,206,222,223,305,339,343,381 The Wnt signaling pathway genes previously identified in familial exudative vitreoretinopathy, including FZD4 and LRP5 , and Norrie Disease Protein (NDP) gene have also been explored with positive associations with ROP including stage 4/5 ROP in several studies; 90,97,104,172,173,218,244,342 however, there have been only a few genetic studies with adequate sample size and refined inclusion criteria. A large genetic cohort study identified SNPs in the intronic region of brain-derived neurotrophic factor (BDNF) gene as associated with treatment-requiring ROP, which warrants further studies on functional effects of intronic variants of BDNF and replication studies.…”

Section: Genetic Risk Factorsmentioning

confidence: 99%

Retinopathy of prematurity: a review of risk factors and their clinical significance

Kim

Port

Swan

et al. 2018

Survey of Ophthalmology

414

337

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a retinal vasoproliferative disease that affects premature infants. Despite improvements in neonatal care and management guidelines, ROP remains a leading cause of childhood blindness worldwide. Current screening guidelines are primarily based on two risk factors: birth weight and gestational age; however, many investigators have suggested other risk factors, including maternal factors, prenatal and perinatal factors, demographics, medical interventions, comorbidities of prematurity, nutrition, and genetic factors. We review the existing literature addressing various possible ROP risk factors. Although there have been contradictory reports, and the risk may vary between different populations, understanding ROP risk factors is essential to develop predictive models, to gain insights into pathophysiology of retinal vascular diseases and diseases of prematurity, and to determine future directions in management of and research in ROP.

show abstract

“…indomethacin did not affect the expression levels of the vascular endothelial growth factor system in ductus arteriosus endothelial cells. 7 Several authors investigated vascular endothelial growth factor polymorphisms and their potential association with neonatal morbidities such as bronchopulmonary dysplasia, [10][11][12] retinopathy of prematurity, 8,9 and intraventricular haemorrhage 16 in preterm infants. However, the role of the vascular endothelial growth factor polymorphism rs2010963 on patent ductus arteriosus incidence and treatment success rates has not been previously investigated.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 We have recently shown that ibuprofen and indomethacin differentially regulate vascular endothelial growth factor and its receptors in primary endothelial cells of the rat ductus arteriosus. 7 In addition, several studies discussed vascular endothelial growth factor polymorphisms as potential risk factors for several diseases in neonates, including retinopathy of prematurity 8,9 and bronchopulmonary dysplasia. [10][11][12] The aim of the current study was to investigate the incidence of the vascular endothelial growth factor polymorphism rs2010963 status in a large cohort of preterm infants with and without patent ductus arteriosus and its potential association with cyclooxygenase inhibitor treatment success rates.…”

mentioning

confidence: 99%

Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants

et al. 2019

View full text Add to dashboard Cite

Background:Vascular endothelial growth factor is critically involved in ductus arteriosus closure. Polymorphisms in the vascular endothelial growth factor gene have been associated with several diseases in neonates and adults.Aim:Herein, we investigated if vascular endothelial growth factor polymorphism rs2010963 status is associated with patent ductus arteriosus incidence and/or pharmacological treatment success.Methods:We assessed rs2010963 status in 814 preterm infants (<1500 g birth weight) by means of restriction fragment length polymorphism analysis. DNA samples were obtained from dry-spot cards used for the German national newborn screening program. Clinical data were obtained by retrospective chart review.Results:We could not find any statistically significant difference in the incidence of patent ductus arteriosus depending on vascular endothelial growth factor rs2010963 polymorphism status. Furthermore, no statistically significant associations between vascular endothelial growth factor polymorphism rs2010963 status and cyclooxygenase inhibitor treatment success were observed.Conclusion:Our results indicate that there is no association between vascular endothelial growth factor polymorphism rs2010963 status and the occurrence of patent ductus arteriosus or the response to cyclooxygenase inhibitor treatment in a large cohort of preterm infants. Additional studies are needed to determine the role of genetic factors on patent ductus arteriosus incidence and treatment response.

show abstract

Polymorphisms of Vascular Endothelial Growth Factor and Retinopathy of Prematurity

Abstract: The results support the hypothesis that the carrier state of VEGF 634 C/G polymorphism has an impact on the risk of ROP in infants. A broader study may suggest that this marker could be used as an indicator in the screening for ROP.

Cited by 14 publications

References 39 publications

A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases

A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases

Retinopathy of prematurity: a review of risk factors and their clinical significance

Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants

Contact Info

Product

Resources

About